Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

New comers in the early breast cancer setting: Checkpoint and PARP inhibitors

Which checkpoint inhibitor, in which biomarker sub-group and when: What is approved, what is coming and what are the trials telling us

Date

12 May 2023

Session

New comers in the early breast cancer setting: Checkpoint and PARP inhibitors

Topics

Tumour Site

Breast Cancer

Presenters

Sibylle Loibl

Authors

S. Loibl

Author affiliations

German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg/DE

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

12 May 2023

How to improve outcomes in those non-pCR after NACT+CPI

Presenter: Sheeba Irshad

Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors

Resources:

Slides

Webcast

12 May 2023

PARP inhibition in early breast cancer: What have we learned and how can we move forward?

Presenter: Andrew Tutt

Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors

Resources:

Slides

Webcast

12 May 2023

PARP inhibitor combination strategies in early breast cancer: Rationale and results to date

Presenter: Kevin Punie

Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors

Resources:

Slides

Webcast

12 May 2023

Q&A and discussion

Presenter: To be Announced

Session: New comers in the early breast cancer setting: Checkpoint and PARP inhibitors

Resources:

Webcast